Literature DB >> 3447129

Effect of flupirtine maleate on the nociceptive pathway, EEG, evoked potentials and polysynaptic reflexes in laboratory animals.

R Gordon1, R D Sofia, W Diamantis.   

Abstract

Flupirtine maleate (3, 6 and 10 mg/kg, i.v.) elevated the pain threshold following electrical stimulation of rabbit tooth pulp with a peak effect at 10 minutes, suggesting central analgesic activity. Codeine (1, 3 and 6 mg/kg, i.v.), but not zomepirac (3, 6 and 10 mg/kg, i.v.), was also effective. In the cat, electrical stimulation of the tooth pulp or the contralateral sciatic nerve (central and peripheral nociceptive pathways, respectively) results in evoked potentials (activation) in the midbrain (MRF), thalamus (VPL) and sensory cortex. Flupirtine maleate (1 mg/kg, i.v.) did not alter the evoked responses. But at 3 and 6 mg/kg, i.v. it effectively blocked activation in the MRF, VPL and sensory cortex, primarily following tooth pulp stimulation rather than after sciatic nerve stimulation, suggesting that flupirtine was a selective antagonist of the central nociceptive pathway. Furthermore, in the cat, flupirtine at 3 mg/kg, i.v. blocked cortical and hippocampal arousal (activation) following MRF stimulation. At 6 and 10 mg/kg it partially antagonized the linguomandibular reflex (central polysynaptic reflex) but had little or no effect on the flexor reflex (peripheral polysynaptic reflex). The results of these investigations demonstrate the central nervous system activity of flupirtine maleate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3447129

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  2 in total

Review 1.  Flupirtine, a re-discovered drug, revisited.

Authors:  Istvan Szelenyi
Journal:  Inflamm Res       Date:  2013-01-16       Impact factor: 4.575

Review 2.  Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.

Authors:  H A Friedel; A Fitton
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.